Liquidia Co. (NASDAQ:LQDA) CFO Sells $275,298.60 in Stock

Liquidia Co. (NASDAQ:LQDA) CFO Michael Kaseta sold 23,370 shares of the stock in a transaction dated Tuesday, January 14th. The stock was sold at an average price of $11.78, for a total transaction of $275,298.60. Following the completion of the transaction, the chief financial officer now owns 401,755 shares of the company’s stock, valued at approximately $4,732,673.90. The trade was a 5.50 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Michael Kaseta also recently made the following trade(s):

• On Monday, December 2nd, Michael Kaseta sold 1,091 shares of Liquidia stock. The stock was sold at an average price of $11.51, for a total transaction of $12,557.41.

Liquidia Stock Performance

Shares of NASDAQ:LQDA opened at $12.51 on Friday. The firm has a market cap of $1.06 billion, a price-to-earnings ratio of -7.67 and a beta of 0.23. The business has a 50-day simple moving average of $11.26 and a two-hundred day simple moving average of $11.03. Liquidia Co. has a fifty-two week low of $8.26 and a fifty-two week high of $16.99.

Wall Street Analyst Weigh In

LQDA has been the topic of a number of analyst reports. Scotiabank initiated coverage on Liquidia in a research report on Wednesday, October 16th. They issued a “sector outperform” rating and a $30.00 price target on the stock. Lifesci Capital initiated coverage on Liquidia in a research note on Thursday, October 3rd. They issued an “outperform” rating and a $30.00 target price on the stock. Needham & Company LLC reaffirmed a “buy” rating and issued a $19.00 price target on shares of Liquidia in a research report on Thursday, January 9th. Wells Fargo & Company assumed coverage on shares of Liquidia in a research note on Friday, December 20th. They issued an “overweight” rating and a $20.00 price target on the stock. Finally, HC Wainwright restated a “buy” rating and set a $29.00 price objective on shares of Liquidia in a research note on Thursday, November 14th. One research analyst has rated the stock with a hold rating, six have given a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Liquidia currently has an average rating of “Buy” and a consensus price target of $25.38.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in LQDA. Whitcomb & Hess Inc. boosted its holdings in Liquidia by 10.2% in the third quarter. Whitcomb & Hess Inc. now owns 11,599 shares of the company’s stock worth $116,000 after purchasing an additional 1,074 shares during the last quarter. Arizona State Retirement System boosted its stake in shares of Liquidia by 10.7% in the 2nd quarter. Arizona State Retirement System now owns 13,842 shares of the company’s stock worth $166,000 after buying an additional 1,341 shares during the last quarter. Quest Partners LLC bought a new stake in shares of Liquidia in the second quarter worth $27,000. Profund Advisors LLC increased its position in Liquidia by 31.6% during the second quarter. Profund Advisors LLC now owns 14,434 shares of the company’s stock valued at $173,000 after acquiring an additional 3,466 shares during the last quarter. Finally, DMC Group LLC boosted its position in Liquidia by 36.7% in the third quarter. DMC Group LLC now owns 13,883 shares of the company’s stock worth $139,000 after purchasing an additional 3,725 shares during the last quarter. 64.54% of the stock is owned by hedge funds and other institutional investors.

Liquidia Company Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).